» Articles » PMID: 31036990

Monitoring Protocols for Cochlear Toxicity

Overview
Journal Semin Hear
Date 2019 May 1
PMID 31036990
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

The need for monitoring hearing and auditory function during drug therapy and other treatments that have the potential to cause hearing loss is well documented. Besides the main purpose of ototoxic monitoring, which is to provide feedback to the attending physician about the effects the treatment is having on the auditory system, it is also helpful in setting expectations for the patient and his/her family about the communication issues that may result from the drug therapy. This article will review tests available to an audiologist, both subjective and objective, that can be used to effectively monitor hearing levels and auditory function during treatment. Published guidelines and various ototoxic monitoring protocols are reviewed regarding tests administered, what constitutes a significant change in test results and how these findings are reported, and the impact significant changes may have on the course of treatment. Test protocols from different institutions are compared for both similarities and contrasts. Effective scheduling and test location are key to a successful monitoring program. Finally, the need to streamline ototoxic monitoring of hearing and auditory function to reduce test time and make it less stressful and tiresome on the patient will be considered.

Citing Articles

The Impact of Monoclonal Antibody Usage on Hearing Outcomes: A Systematic Review.

Arya P, Salmeron Y, Quimby A, Wong K, Brant J, Hwa T Laryngoscope. 2024; 135(2):491-506.

PMID: 39268884 PMC: 11725704. DOI: 10.1002/lary.31763.


Ototoxicity: a high risk to auditory function that needs to be monitored in drug development.

Pasdelou M, Byelyayeva L, Malmstrom S, Pucheu S, Peytavy M, Laullier H Front Mol Neurosci. 2024; 17:1379743.

PMID: 38756707 PMC: 11096496. DOI: 10.3389/fnmol.2024.1379743.


Cisplatin-associated ototoxicity amongst cervical cancer patients: A prospective cohort study in south Africa.

Paken J, Govender C, Pillay M, Feyasa M, Sewram V PLoS One. 2023; 18(4):e0283639.

PMID: 37014872 PMC: 10072443. DOI: 10.1371/journal.pone.0283639.


Noise-induced hearing disorders: Clinical and investigational tools.

Le Prell C, Clavier O, Bao J J Acoust Soc Am. 2023; 153(1):711.

PMID: 36732240 PMC: 9889121. DOI: 10.1121/10.0017002.


Cisplatin-associated ototoxicity: perspectives from a single institution cervical cancer cohort and implications for developing a locally responsive monitoring programme in a public healthcare setting.

Paken J, Govender C, Pillay M, Sewram V BMC Health Serv Res. 2022; 22(1):791.

PMID: 35717191 PMC: 9206275. DOI: 10.1186/s12913-022-08099-8.


References
1.
Arslan E, Orzan E, Santarelli R . Global problem of drug-induced hearing loss. Ann N Y Acad Sci. 2000; 884:1-14. DOI: 10.1111/j.1749-6632.1999.tb00277.x. View

2.
Fausti S, Flick C, Bobal A, Ellingson R, Henry J, Mitchell C . Comparison of ABR stimuli for the early detection of ototoxicity: conventional clicks compared with high frequency clicks and single frequency tonebursts. J Am Acad Audiol. 2003; 14(5):239-50; quiz 281-2. View

3.
STUDEBAKER G . Placement of vibrator in bone-conduction testing. J Speech Hear Res. 1962; 5:321-31. DOI: 10.1044/jshr.0504.321. View

4.
Fischel-Ghodsian N . Genetic factors in aminoglycoside toxicity. Pharmacogenomics. 2005; 6(1):27-36. DOI: 10.1517/14622416.6.1.27. View

5.
Fausti S, Wilmington D, Helt P, Helt W, Konrad-Martin D . Hearing health and care: the need for improved hearing loss prevention and hearing conservation practices. J Rehabil Res Dev. 2006; 42(4 Suppl 2):45-62. DOI: 10.1682/jrrd.2005.02.0039. View